A study published in JAMA Internal Medicine investigated the association between use of GLP-1 receptor agonists and the risk of suicide death in routine clinical practice. The study used nationwide register data from Sweden and Denmark, covering adults aged 18 to 84 years who initiated treatment with GLP-1 receptor agonists or SGLT2 inhibitors between 2013 and 2021. The primary outcome was suicide death, with secondary outcomes including suicide death and nonfatal self-harm, and incident depression and anxiety-related disorders. The study found no statistically significant association between GLP-1 receptor agonist use and increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders. The weighted incidence rate of suicide death was 0.23 events per 1000 person-years for GLP-1 receptor agonist users and 0.18 events per 1000 person-years for SGLT2 inhibitor users, with a hazard ratio of 1.25 (95% CI, 0.83-1.88). The study concluded that GLP-1 receptor agonists are not associated with an increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders. The study had limitations, including the possibility of unmeasured confounding and the inability to assess small risk increases. The findings suggest that the absolute risk of suicide death in patients using GLP-1 receptor agonists is low, and any potential risk increase would be small. The study supports the conclusions of the European Medicines Agency and the US Food and Drug Administration that there is no causal association between GLP-1 receptor agonist use and suicidal thoughts or actions.A study published in JAMA Internal Medicine investigated the association between use of GLP-1 receptor agonists and the risk of suicide death in routine clinical practice. The study used nationwide register data from Sweden and Denmark, covering adults aged 18 to 84 years who initiated treatment with GLP-1 receptor agonists or SGLT2 inhibitors between 2013 and 2021. The primary outcome was suicide death, with secondary outcomes including suicide death and nonfatal self-harm, and incident depression and anxiety-related disorders. The study found no statistically significant association between GLP-1 receptor agonist use and increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders. The weighted incidence rate of suicide death was 0.23 events per 1000 person-years for GLP-1 receptor agonist users and 0.18 events per 1000 person-years for SGLT2 inhibitor users, with a hazard ratio of 1.25 (95% CI, 0.83-1.88). The study concluded that GLP-1 receptor agonists are not associated with an increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders. The study had limitations, including the possibility of unmeasured confounding and the inability to assess small risk increases. The findings suggest that the absolute risk of suicide death in patients using GLP-1 receptor agonists is low, and any potential risk increase would be small. The study supports the conclusions of the European Medicines Agency and the US Food and Drug Administration that there is no causal association between GLP-1 receptor agonist use and suicidal thoughts or actions.